C’Dots, silica-encased nanoparticles developed in the lab of engineering professor Ulrich Wiesner, have just begun their first therapeutic human clinical trial. They’re being further developed by Elucida Oncology Inc., a company co-founded by Wiesner.
Cornell is launching a bold new initiative in artificial intelligence that will expand faculty working both in core areas, as well as the nearly unlimited domains affected by advances in AI.
Vanessa Bohns, a social psychologist and professor of organizational behavior at the ILR School, says there are ways – starting with intentional rest and recovery – to recalibrate after nearly two years of a pandemic-induced, always-on work mindset.
FARVets, a nonprofit run through the College of Veterinary Medicine to address animal overpopulation with spay-neuter clinics and vaccinations, has extended its reach in New York state as it has had to limit international programming because of the COVID-19 pandemic.
A Cornell program is playing a key role in a project to make rice more resilient to climate change and increase production in West Africa, thanks to a four-year, $14 million grant from the Adaptation Fund.
The nine undergrads will be arriving on campus through December, thanks to robust international and cross-campus collaborations. Cornell has pledged support until they graduate.
A new Cornell-led study battled strains of yeast manipulated to release different toxins at tunable and controlled rates, finding that the strain with the stronger toxin can only defeat another if its initial invading population exceeds a critical frequency or size.
